A rotation from tech into healthcare is underway as strong earnings and technical breakouts lift several stocks; Benzinga spotlights six momentum leaders. Cardinal Health (CAH, $48bn) jumped after an Oct. 30 Q3 beat (EPS ~16% above consensus) and is up ~70% YTD; Guardant Health (GH) received FDA companion-diagnostic approval and reported a record $265m quarter (+38% YoY) with a narrower loss; Abivax (ABVX) exploded higher after positive Phase 3 obefazimod data and analyst price-target upgrades; Medpace (MEDP) posted consecutive beats (Q3 revenue +23% YoY) and a refilling backlog; Elanco (ELAN) beat and raised guidance on double-digit segment growth; and GeneDx (WGS) raised revenue and margin guidance after back-to-back ~$100m quarters and is nearing a $4bn market cap. Collectively the report suggests the move into healthcare is supported by both fundamentals and technicals, with pullbacks to the 50-day SMA flagged as potential entry points.
Market flows show an early-stage rotation out of high-flying technology names and into healthcare, supported by both earnings beats and technical breakouts; Benzinga’s coverage highlights a bullish sentiment score of 0.65 even as the aggregate market-impact score is moderate at 0.35. Several names are exhibiting momentum: Cardinal Health (CAH) — a $48 billion market-cap wholesaler with more than $50 billion in quarterly sales since Q1 2023 — is up >70% YTD and jumped ~15% on an Oct. 30 Q3 report where EPS beat consensus by more than 16%. Guardant Health (GH) reported a record $265 million quarter (+38% YoY) and secured FDA approval for Guardant360 CDx, while Medpace (MEDP) posted Q2 revenue ~12% ahead of expectations and Q3 revenue +23% YoY, supporting a >75% YTD gain. Biotech/high-beta names are driving headline returns: Abivax (ABVX) surged ~600% in a session after July Phase 3 results and has seen another 60% move in three months amid analyst target increases, Elanco (ELAN) beat and raised guidance with double-digit segment growth despite a recent pullback to the 50-day SMA, and GeneDx (WGS) now approaches a ~$4 billion market cap after back-to-back ~$100 million quarters and upward guidance for revenue and adjusted gross margins. The technical picture is consistent across the group: multiple stocks have established support around the 50-day simple moving average and saw trend acceleration pre-earnings, implying earnings-driven confirmation is a primary catalyst. Risks include heightened idiosyncratic volatility in small-cap and biotech names (ABVX and WGS), the potential for profit-taking after outsized single-session moves, and the limited broader-market footprint implied by the moderate market-impact score, meaning sector strength could reverse if macro sentiment shifts. Investors should therefore treat the move as fundamentally supported but catalyst-dependent, prioritize names with repeatable revenue beats and visible backlogs (CAH, MEDP, ELAN), and expect continued trading opportunities around 50-day SMA pullbacks while using strict position sizing and hedges for high-beta biotech exposure.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment
